Zobrazeno 1 - 10 of 33 pro vyhledávání: '"Tadafumi, Terada"'
2
A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity
Autor: Tadafumi Terada, Shuichi Ohkubo, Norio Masuko, Shinji Okazaki, Yoshikazu Sugimoto, Yoshimi Aoyagi, Yuji Yamada, Konstanty Wierzba, Makoto Kitade, Kentaro Nagai
Publikováno v: Cancer Science. 96:614-619
The Cdc25 dual-specificity phosphatases are key regulators of cell cycle progression through activation of cyclin-dependent kinases (Cdk). Three homologs exist in humans: Cdc25A, Cdc25B, and Cdc25C. Cdc25A and Cdc25B have oncogenic properties and are
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b97aa905beeac2428614990e2306c41
https://doi.org/10.1111/j.1349-7006.2005.00086.x
Zobrazit plný text záznamu
3
Napthalimidobenzamide DB-51630: a novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity
Autor: Yoshikazu Sugimoto, Tadafumi Terada, Kenji Suzuki, Wakida Motoji, Kazuharu Noguchi, Konstanty Wierzba, Yoshihiro Uto, Kenji Kitazato, Hideko Nagasawa, Yuji Yamada, Tetsuji Asao, Hitoshi Hori
Publikováno v: Bioorganic & Medicinal Chemistry. 13:4014-4021
Control of gene expression by small molecule compounds is a novel therapeutic strategy for cancer and usually it requires the presence of specific molecular recognition. The development of the compounds preferentially binding to the specific DNA sequ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da28941e0e6e984fdaadded51a5abce9
https://doi.org/10.1016/j.bmc.2005.03.053
Zobrazit plný text záznamu
4
TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect
Autor: Yasuji Yamamoto, Jiro Shibata, Kazuhiko Yonekura, Kouji Sato, Akihiro Hashimoto, Yoshimi Aoyagi, Konstanty Wierzba, Shingo Yano, Tetsuji Asao, Aman U. Buzdar, Tadafumi Terada
Publikováno v: Clinical Cancer Research. 11:315-322
Purpose: Investigators are currently conducting phase II trials on TAS-108, a novel oral steroidal antiestrogenic agent. The purpose of this study is to investigate the molecular and pharmacologic properties of TAS-108 comparedwith other antiestrogen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::328da84c2241bf963ffc1c67357eda99
https://doi.org/10.1158/1078-0432.315.11.1
Zobrazit plný text záznamu
5
Antitumor agents. 3. Synthesis and biological activity of 4.beta.-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents
Autor: Yasuhiro Yamada, K. Fujimoto, Tadafumi Terada, M. Nomura, T. Kobunai, R. Yamazaki, Yoshikazu Sugimoto, J. Shibata, Junichi Yamashita, Konstanty Wierzba
Publikováno v: Journal of Medicinal Chemistry. 36:1689-1699
A series of 4 beta-alkyl (7-10), 4 beta-aminoalkyl (12a-y), and 4 beta-amidoalkyl derivatives (14a-g) of 4'-O-demethyl-4-desoxypodophyllotoxin have been synthesized, and their cytotoxicity, inhibition of DNA topoisomerase II (Topo II), and tubulin po
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a09b4872d76134ba8fcae6b1e2bd861
https://doi.org/10.1021/jm00064a002
Zobrazit plný text záznamu
7
Antitumor Agents. I. DNA Topoisomerase II Inhibitory Activity and the Structural Relationship of Podophyllotoxin Derivatives as Antitumor Agents
Autor: Fujimoto Katsuhiko, Takashi Kobunai, Konstanty Wierzba, Junichi Yamashita, Makoto Nomura, Setsuo Takeda, Tadafumi Terada, Yuji Yamada, Hideo Yamaguchi
Publikováno v: Chemical and Pharmaceutical Bulletin. 40:2720-2727
Various podophyllotoxin derivatives from desoxypodophyllotoxin (DPT) were synthesized to examine the structural relationships between the biological significance (cytotoxic effect, effects on DNA topoisomerase II and tubulin polymerization) in vitro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c51d5350849868e229f80fb3864a0c4e
https://doi.org/10.1248/cpb.40.2720
Zobrazit plný text záznamu
8
Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells
Autor: Tadafumi Terada, Hiroto Fukushima, Yuji Yamada, Kazuyuki Hirano, Shinji Oie, Fumihito Hosoi, Michihiko Kuwano, Masamichi Kojiro, Hirohisa Yano, Mayumi Ono, Yuichiro Maruyama
Publikováno v: Molecular cancer therapeutics. 6(8)
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU) and its activity is closely associated with cellular sensitivity to 5-FU. This study examines the role of DPD in the antiproliferative effect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05ff52493245898085c35c6f623bf323
https://pubmed.ncbi.nlm.nih.gov/17699726
Zobrazit plný text záznamu
9
The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-α
Autor: Tadafumi Terada, Yuichiro Maruyama, Mayumi Ono, Kazuyuki Hirano, Yuji Yamada, Takato Ueno, Hirohisa Yano, Michihiko Kuwano, Shinji Oie, Masamichi Kojiro
Publikováno v: International Journal of Oncology.
Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13b8dad9bffff34cb3a7d30a0dcb57b1
https://doi.org/10.3892/ijo.29.6.1469
Zobrazit plný text záznamu
10
The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha
Autor: Shinji, Oie, Mayumi, Ono, Hirohisa, Yano, Yuichiro, Maruyama, Tadafumi, Terada, Yuji, Yamada, Takato, Ueno, Masamichi, Kojiro, Kazuyuki, Hirano, Michihiko, Kuwano
Publikováno v: International journal of oncology. 29(6)
Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a7152090c4bda75a190985d95642c86b
https://pubmed.ncbi.nlm.nih.gov/17088986
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje